Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.405 USD | +0.54% | -2.93% | +166.87% |
May. 28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+166.87% | 968M | |
+15.75% | 118B | |
+13.84% | 106B | |
-2.21% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-16.77% | 15.56B | |
+6.43% | 13.63B | |
+29.04% | 12.27B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q4 Revenue $13.5M, vs. Street Est of $11.4M